{"id":827645,"date":"2025-03-19T16:05:14","date_gmt":"2025-03-19T20:05:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"modified":"2025-03-19T16:05:14","modified_gmt":"2025-03-19T20:05:14","slug":"corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","title":{"rendered":"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., March  19, 2025  (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.<\/p>\n<p>A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-bbim6_aMojigBmiYwWuZWrXBsQj-8j5LBxcUppjh8yaVlHiEcl3lsrvzl5KFt5mlTdWI2nATgYPeCVGRsqjtAj0aM8HV-guT9aaclR6UZ4=\" rel=\"nofollow\" target=\"_blank\">investor relations<\/a> section of the Corvus website.<\/p>\n<p>\n        <strong>About\u00a0Corvus Pharmaceuticals<\/strong><br \/>\n        <br \/>Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2wS69FN7_bOQDDIwfuEFx0b2MDeh9O3h_ZT5A8ECzLRdYDc8Ky2KV83bzXZQ_b5U9COVLUwsTlaZS8NsTgknDNWnJiFgQ3SfvkU-ZA-E-ZoEkYzKeiO36S7k3cwGrpSp0uChOTiQEFgWmqwqrwDEGOubFdt3GrdLlKZOX0e_y-UtzEyDMMXhvhaHdu61iHKUMhXCUMG3GJjH7Xi9WUXEnlRLI6wjJI9guUr8CIWtMHuwz46z1wTs0bU9Uuq8wO0CpH3xI_B4le8eUsTdDxmiAA==\" rel=\"nofollow\" target=\"_blank\">www.corvuspharma.com<\/a>.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Leiv Lea<br \/>Chief Financial Officer<br \/>Corvus Pharmaceuticals, Inc.<br \/>+1-650-900-4522<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ATF4qoulBpyz9lunOInCRD71SQ_PBL39UdOyyiegvqR2Fv3SIAB1SFglwGY1ar-w_7UBDDeU7kcXu9s7mbhDTWu8PDT3qS9H4ktFSCbrJYA=\" rel=\"nofollow\" target=\"_blank\">llea@corvuspharma.com<\/a><\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Sheryl Seapy<br \/>Real Chemistry<br \/>+1-949-903-4750<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hPHiEWvqM3nacRPtQQQ5EiI_YFMsbDzIAmplI749WOIjeI0dL6xUl5XKtfeGsr6UNaxFXuLEwYtF3oJHjfCntxtYfql0xg7535fJKyZPgFH32CiGP8VFGRPE7lINybdc\" rel=\"nofollow\" target=\"_blank\">sseapy@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmRjMGFiMGMtNTAxZS00OWViLWJkZmItMzI5YjIyNmE4ODBkLTEwMzc1NjUtMjAyNS0wMy0xOS1lbg==\/tiny\/Corvus-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET. A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About\u00a0Corvus Pharmaceuticals Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827645","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET. A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About\u00a0Corvus Pharmaceuticals Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to &hellip; Continue reading &quot;Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T20:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\",\"datePublished\":\"2025-03-19T20:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"wordCount\":208,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"name\":\"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=\",\"datePublished\":\"2025-03-19T20:05:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET. A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About\u00a0Corvus Pharmaceuticals Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to &hellip; Continue reading \"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T20:05:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference","datePublished":"2025-03-19T20:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"wordCount":208,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","name":"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=","datePublished":"2025-03-19T20:05:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg5MSM2ODA5OTE0IzIwMjU5OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827645"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827645\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}